![Image](https://english.sunonews.tv/enews/2024/May/05-08-24/news_big_images/health_60083208.jpg)
The company also said it would proceed to withdraw the vaccine Vaxzevria’s marketing authorizations within Europe.
"As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.
According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.
The firm’s application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.
![Image](https://english.sunonews.tv/enews/2024/September/09-04-24/news_big_images/health_13407253.jpg)
![Image](https://english.sunonews.tv/enews/2024/September/09-02-24/news_big_images/world_26012029.jpg)
![Image](https://english.sunonews.tv/enews/2024/August/08-29-24/news_big_images/world_16128111.jpg)
![Image](https://english.sunonews.tv/enews/2024/August/08-28-24/news_big_images/world_22338258.jpg)